Sarepta Therapeutics Inc
NASDAQ:SRPT

Watchlist Manager
Sarepta Therapeutics Inc Logo
Sarepta Therapeutics Inc
NASDAQ:SRPT
Watchlist
Price: 126.27 USD Market Closed
Market Cap: 12.1B USD

Sarepta Therapeutics Inc
Investor Relations

Sarepta Therapeutics Inc. is a company firmly rooted in the ambitious quest to change the lives of those grappling with rare genetic disorders, particularly focusing on Duchenne muscular dystrophy (DMD). The scientists and innovators at Sarepta are driven by their expertise in genetic medicine, utilizing cutting-edge technologies such as exon skipping, gene therapy, and RNA-targeted therapeutics to develop treatments that combat the underlying causes of these debilitating diseases. The company's journey is underscored by its commitment to not only advancing science but also accelerating the delivery of hope to patients and families affected by these life-limiting conditions.

Central to Sarepta's business model is the commercialization of its approved therapies, alongside an expansive pipeline of potential treatments still in various stages of research and development. By prioritizing strategic partnerships and leveraging their robust intellectual property portfolio, Sarepta translates pioneering science into tangible healthcare solutions. Revenue is chiefly generated through the sales of its FDA-approved DMD treatments, capturing a market niche due to the lack of viable alternatives. As Sarepta looks toward future horizons, the company remains steadfast in its mission to scale new heights in genetic medicine, aiming to redefine the standard of care for rare neuromuscular diseases worldwide.

Show more
Loading

Earnings Calls

2024 Q3
Nov 6, 2024
Show Transcript
Previous
Next
Sarepta Therapeutics Reports Strong Q3 Growth Driven by ELEVIDYS and PMO Sales
2024 Q3
Nov 6, 2024

Sarepta Therapeutics delivered a robust performance in Q3 2024, achieving $430 million in total net product revenue, a 39% increase year-over-year. ELEVIDYS sales surged to $181 million, reflecting a nearly 50% increase from Q2, outpacing previous guidance. PMO sales also performed well, contributing approximately $249 million. The company remains confident in maintaining its guidance for Q4 and expects total revenue in 2025 to reach $3 billion, with two-thirds from ELEVIDYS. Despite discontinuing the SRP-5051 program due to safety concerns, Sarepta is optimistic about its pipeline, including three new limb-girdle muscular dystrophy therapies set for clinical trials in the coming months.

Show Full Analysis

Management

Mr. Douglas S. Ingram Esq.
President, CEO & Director
No Bio Available
Mr. Ian Michael Estepan
Executive VP & CFO
No Bio Available
Mr. Bilal Arif
Executive VP & Chief Technical Operations Officer
No Bio Available
Ms. Francesca T. Nolan
Executive Director of Investor Relations and Corporate Communications
No Bio Available
Ms. Alison Nasisi
Executive VP & Chief People Officer
No Bio Available
Dr. Diane L. Berry Ph.D.
Executive VP and Chief of Global Policy & Advocacy Officer
No Bio Available
Mr. Dallan Murray
Executive VP & Chief Customer Officer
No Bio Available
Mr. Will Tilton
Senior VP, Head of Strategy & Chief of Staff
No Bio Available
Mary Jenkins
Senior Manager of Investor Relations
No Bio Available

Contacts

Address
MASSACHUSETTS
Cambridge
215 1st St Ste 415
Contacts
+16172744000.0
www.sarepta.com